It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Understanding what makes up a financial plan is essential for effective management. Discover the key aspects that contribute to success.
23,092 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Prices may look flat, but the real bill for home buying in 2026 is higher. This guide reveals where data lies, what b...
Two specialty retailers sit on opposite ends of the consumer tech spectrum. By unpacking their revenue trends, invest...
A single chokepoint can reshape markets. When the strait hormuz closure sent oil prices higher, energy shares jumped ...
As AI models scale, memory bandwidth becomes the bottleneck. This article digs into Nvidia's role in HBM4, the chatte...
In a year of sharp rotation, the Vanguard FTSE DEVELOPED Markets ETF ex US is outperforming the S&P 500—yet the decad...
Across Chicago and beyond, AI readiness in schools mirrors economic divides. This report examines funding gaps, acces...
As AI accelerates, investors wonder if Sandisk could become the next Nvidia. This article dives into Sandisk's AI-sto...
No stock goes straight up, and Walmart’s latest report is a perfect example. Strong e-commerce gains meet a cautious ...
A close look at on-chain data shows Vitalik Buterin holding roughly 240,000 ETH, with recent large withdrawals and a ...
Microsoft reported a sharp jump in capital spending as it doubles down on AI infrastructure. Four-quarter CapEx now t...
A U.S. Halloween costume distributor explains how volatile tariffs and shifting supply chains are raising costs and r...